The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Combining CAR-T with T cell-engaging bispecific antibodies to enhance efficacy in CLL murine models
In this interview, Martina Seiffert, PhD, German Cancer Research Center, Heidelberg, Germany, comments on an investigation into a treatment approach in which CD19 CAR T-cells (CAR-T) are combined with bispecific antibody (bsAb) treatment to improve efficacy. The therapy approach has been investigated in murine models of chronic lymphocytic leukemia (CLL) and in ex vivo primary culture models of CLL lymph node samples. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
